| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PRKAR1A |
| Uniprot No | P10644 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-381 aa |
| 活性数据 | MESGSTAASE EARSLRECEL YVQKHNIQAL LKDSIVQLCT ARPERPMAFL REYFERLEKE EAKQIQNLQK AGTRTDSRED EISPPPPNPV VKGRRRRGAI SAEVYTEEDA ASYVRKVIPK DYKTMAALAK AIEKNVLFSH LDDNERSDIF DAMFSVSFIA GETVIQQGDE GDNFYVIDQG ETDVYVNNEW ATSVGEGGSF GELALIYGTP RAATVKAKTN VKLWGIDRDS YRRILMGSTL RKRKMYEEFL SKVSILESLD KWERLTVADA LEPVQFEDGQ KIVVQGEPGD EFFIILEGSA AVLQRRSENE EFVEVGRLGP SDYFGEIALL MNRPRAATVV ARGPLKCVKL DRPRFERVLG PCSDILKRNI QQYNSFVSLS V |
| 分子量 | 42.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PRKAR1A蛋白的3篇代表性文献的简要列举：
1. **"Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex"**
- **作者**: Kirschner LS et al.
- **摘要**: 本研究首次发现PRKAR1A基因失活突变导致Carney复合征(一种罕见内分泌肿瘤综合征)，揭示了PRKAR1A通过调控PKA活性参与肿瘤发生，突变导致cAMP/PKA信号通路异常。
2. **"The role of cyclic AMP signaling in cardiac dysfunction and heart failure: PRKAR1A as a key regulator"**
- **作者**: Marx SO et al.
- **摘要**: 探讨PRKAR1A在心脏PKA信号中的核心作用，发现其缺失或突变导致心肌细胞凋亡和纤维化，提出PRKAR1A异常与心力衰竭的潜在关联机制。
3. **"Structure and function of the regulatory subunit of protein kinase A: insights from PRKAR1A mutations"**
- **作者**: Taylor SS et al.
- **摘要**: 分析PRKAR1A蛋白的三维结构及其与cAMP的相互作用，揭示突变如何破坏PKA全酶稳定性，进而影响下游靶标磷酸化和细胞周期调控。
如需更多文献或扩展内容，可进一步说明方向(如疾病模型或分子机制)～
PRKAR1A (Protein Kinase cAMP-Dependent Type I Regulatory Subunit Alpha) is a critical regulatory component of the cAMP-dependent protein kinase A (PKA) complex, which mediates cellular responses to cyclic AMP (cAMP), a key secondary messenger in signal transduction. As one of four regulatory subunits (RIα, RIβ, RIIα, RIIβ), PRKAR1A binds to catalytic subunits in the inactive state, releasing them upon cAMP elevation to activate downstream targets involved in metabolism, gene expression, and cell proliferation.
Mutations in the PRKAR1A gene are linked to genetic disorders like Carney complex, a rare autosomal dominant syndrome characterized by endocrine tumors, cardiac myxomas, and pigmented skin lesions. These mutations often result in haploinsufficiency or dysfunctional protein, disrupting PKA signaling and promoting tumorigenesis. PRKAR1A also interacts with other signaling pathways, including Wnt/β-catenin and mTOR, highlighting its broader regulatory role.
Recombinant human PRKAR1A protein, produced via bacterial or mammalian expression systems, is widely used to study PKA dynamics, screen therapeutic agents targeting cAMP signaling, and develop diagnostic tools for mutation-related diseases. Its structural and functional characterization continues to provide insights into PKA-driven pathologies and potential therapeutic strategies.
×
